

Marc Ychou

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/1138857/publications.pdf](https://exaly.com/author-pdf/1138857/publications.pdf)

Version: 2024-02-01

33
papers

12,372
citations

355432

18
h-index

335069

33
g-index

34
all docs

34
docs citations

34
times ranked

13880
citing authors

#	ARTICLE	IF	CITATIONS
1	FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. <i>New England Journal of Medicine</i> , 2011, 364, 1817-1825.	30.7	6,387
2	FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 2395-2406.	30.7	2,053
3	Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCO Multicenter Phase III Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 1715-1721.	5.3	1,755
4	Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. <i>Nature Medicine</i> , 2014, 20, 430-435.	30.5	596
5	Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. <i>European Journal of Cancer</i> , 2006, 42, 2212-2221.	3.0	493
6	Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. <i>Lancet Oncology</i> , The, 2015, 16, 937-948.	10.2	294
7	Preoperative chemo(radio)therapy versus primary surgery for gastroesophageal adenocarcinoma: Systematic review with meta-analysis combining individual patient and aggregate data. <i>European Journal of Cancer</i> , 2013, 49, 3149-3158.	3.0	151
8	Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study. <i>Oncologist</i> , 2019, 24, 185-192.	4.1	96
9	A Randomized Phase II Trial of Three Intensified Chemotherapy Regimens in First-Line Treatment of Colorectal Cancer Patients with Initially Unresectable or Not Optimally Resectable Liver Metastases. The METHEP Trial. <i>Annals of Surgical Oncology</i> , 2013, 20, 4289-4297.	2.0	83
10	Circulating Tumor Cells and Circulating Tumor DNA Detection in Potentially Resectable Metastatic Colorectal Cancer: A Prospective Ancillary Study to the Unicancer Prodige-14 Trial. <i>Cells</i> , 2019, 8, 516.	4.3	83
11	Cetuximab Plus FOLFIRINOX (ERBIRINOX) as First-Line Treatment for Unresectable Metastatic Colorectal Cancer: A Phase II Trial. <i>Oncologist</i> , 2011, 16, 1557-1564.	4.1	76
12	Multiple Hotspot Mutations Scanning by Single Droplet Digital PCR. <i>Clinical Chemistry</i> , 2018, 64, 317-328.	3.5	43
13	Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as first-line treatment in patients with metastatic pancreatic adenocarcinoma (GATE 1). <i>International Journal of Cancer</i> , 2021, 148, 682-691.	5.4	28
14	Modulating PKC δ Activity to Target Wnt/ β -Catenin Signaling in Colon Cancer. <i>Cancers</i> , 2019, 11, 693.	3.9	24
15	Comparison of early radiological predictors of outcome in patients with colorectal cancer with unresectable hepatic metastases treated with bevacizumab. <i>Gut</i> , 2018, 67, 1095-1102.	13.9	22
16	Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial. <i>British Journal of Cancer</i> , 2022, 126, 1264-1270.	6.6	20
17	A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal Cancer. <i>Targeted Oncology</i> , 2016, 11, 293-308.	3.7	19
18	Stereotactic MR-Guided Radiotherapy for Pancreatic Tumors: Dosimetric Benefit of Adaptation and First Clinical Results in a Prospective Registry Study. <i>Frontiers in Oncology</i> , 2022, 12, 842402.	3.0	19

#	ARTICLE	IF	CITATIONS
19	Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative. <i>European Journal of Cancer</i> , 2020, 130, 63-71.	3.0	17
20	Imaged-guided liver stereotactic body radiotherapy using VMAT and real-time adaptive tumor gating. Concerns about technique and preliminary clinical results. <i>Reports of Practical Oncology and Radiotherapy</i> , 2017, 22, 141-149.	0.7	13
21	Preoperative intraperitoneal oxaliplatin for unresectable peritoneal carcinomatosis of colorectal origin: a pilot study. <i>Pleura and Peritoneum</i> , 2016, 1, 209-215.	1.3	11
22	Disease-free survival as a surrogate for overall survival in neoadjuvant trials of gastroesophageal adenocarcinoma: Pooled analysis of individual patient data from randomised controlled trials. <i>European Journal of Cancer</i> , 2019, 123, 101-111.	3.0	11
23	The oncogenic and druggable hPG80 (Progastrin) is overexpressed in multiple cancers and detected in the blood of patients. <i>EBioMedicine</i> , 2020, 51, 102574.	6.1	11
24	Sorafenib Plus Irinotecan Combination in Patients With RAS-mutated Metastatic Colorectal Cancer Refractory To Standard Combined Chemotherapies: A Multicenter, Randomized Phase 2 Trial (NEXIRI-2/PRODIGE 27). <i>Clinical Colorectal Cancer</i> , 2020, 19, 301-310.e1.	2.4	10
25	Neoadjuvant therapy for gastroesophageal adenocarcinoma. <i>World Journal of Clinical Oncology</i> , 2016, 7, 284.	2.4	10
26	Two-stage hepatectomy for colorectal liver metastases: Pathologic response to preoperative chemotherapy is associated with second-stage completion and longer survival. <i>Surgery</i> , 2019, 165, 703-711.	2.1	7
27	Image-Guided Liver Stereotactic Body Radiotherapy Using VMAT and Real-Time Adaptive Tumor Gating: Evaluation of the Efficacy and Toxicity for Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 4853.	3.9	6
28	CD44v6 Defines a New Population of Circulating Tumor Cells Not Expressing EpCAM. <i>Cancers</i> , 2021, 13, 4966.	3.9	6
29	FOLFIRINOX-R study design: a phase I/II trial of FOLFIRINOX plus regorafenib as first line therapy in patients with unresectable RAS-mutated metastatic colorectal cancer. <i>BMC Cancer</i> , 2021, 21, 564.	2.6	4
30	Quantitative evaluation of liver metastases density on computed tomography: A new tool to evaluate early response to bevacizumab-containing chemotherapy. <i>Digestive and Liver Disease</i> , 2019, 51, 1185-1191.	1.0	3
31	Reproductive Decision-Making in MMR Mutation Carriers After Results Disclosure: Impact of Psychological Status in Childbearing Options. <i>Journal of Genetic Counseling</i> , 2016, 25, 432-442.	1.8	2
32	No Association of Early-Onset Breast or Ovarian Cancer with Early-Onset Cancer in Relatives in BRCA1 or BRCA2 Mutation Families. <i>Genes</i> , 2021, 12, 1100.	2.4	1
33	Regorafenib plus FOLFIRINOX as first-line treatment for patients with RAS-mutant metastatic colorectal cancer (FOLFIRINOX-R trial): a dose-escalation study. <i>Cancer Chemotherapy and Pharmacology</i> , 0, , .	2.4	0